Seattle-based Chinook Therapeutics, purchased earlier this year by Swiss pharmaceutical company Novartis, announced a successful Phase III ALIGN study with its drug, atrasentan. Atrasentan, intended to treat various cancers, fulfilled its purpose of protein reduction in the urine of IgA nephropathy patients.
The ALIGN study, administered blindly, focused on kidney function is impacted by atrasentan. The therapy was added to Novartis’ portfolio after it acquired Chinook Therapeutics in June 2023.